
CCCS holds public consultation on proposed TalkMed acquisition
The consultation will determine whether the acquisition by Tamarind Health would be anti-competitive.
The Competition and Consumer Commission of Singapore (CCCS) is inviting public feedback on the proposed acquisition of TalkMed Group by Tamarind Health Limited (THL).
Last 13 January, CCCS accepted a joint application from both companies for a decision on whether the transaction would be anti-competitive.
THL is active in medical oncology in Singapore. Outside of Singapore, THL’s activities include post-cancer, advisory and consultation services in Malaysia; medical and radiation oncology services in the Philippines, and oncology services in Hong Kong.
Meanwhile, TalkMed provides medical oncology services, adult and paediatric blood disorders treatment, haematologic malignancies and palliative healthcare services. The group also provides cellular and gene therapy-related products and services.
TW Troy Limited, an indirectly wholly-owned subsidiary of THL, will acquire all the issued and paid shares in TalkMed.
Public feedback can be submitted starting 21 January to 5:00 pm on 31 January.